SyntheticMR AB announces intention to publish financial guidance ahead of upcoming rights issue

SyntheticMR intends to publish preliminary, unaudited financial guidance on 19 January 2026 alongside an Information Document ahead of a planned rights issue of approximately SEK 32.8 million. The company has set a timetable: record date 16 Jan, subscription rights trading 20–29 Jan, subscription period 20 Jan–3 Feb, with an expected outcome announcement on 4 Feb and the audited 2025 year-end report due 6 Feb; the guidance is aimed at disclosing available Q4 figures to inform investors prior to the capital raise.

Analysis

Contrarian angles: Consensus may overprice permanent impairment from a single SEK 32.8m raise — if pre-money enterprise value is >SEK 200–300m the dilution is modest (<10%) and post-money balance-sheet repair could be positive for execution; consider accumulating on >15% post-issue sell-off. Historical parallels: small medtechs often see a sharp knee-jerk drop on rights news but recover if guidance meets conservative targets and no further raises are needed within 12 months. Unintended consequence: aggressive selling by non-participating holders can create a buying opportunity for disciplined long-term investors if management demonstrates committed cost control and secured >12 months runway.

Key Decisions for Investors

• If you are an existing shareholder: participate in the rights issue proportionally if SyntheticMR's pre-money enterprise value appears <SEK 250m (to avoid >15% dilution); allocate up to your pro rata holding or 100% of rights available, reassess if anchor investors subscribe >50% (indicator of support).
• Tactical short: establish a 0.5–1.0% NAV short position (via CFDs/borrow) from 19 Jan through 4 Feb, targeting 10–25% downside if guidance disappoints or subscription uptake is weak; hard stop at +12% loss and close by 4 Feb unless new negative catalysts emerge.
• Options hedge: buy 30–45 day put options sized to 0.25% NAV with strikes 10–20% OTM (if liquid) around 19–21 Jan to hedge downside risk during the rights trading/subscription window.
• Relative value pair: go long Getinge (GETI-B.ST) or Elekta (EKTA-B.ST) vs short SyntheticMR (market-cap adjusted) from 20 Jan to 4 Feb to capture divergence driven by funding risk; size 1:1 exposure and reduce after rights outcome.
• Post-issue accumulation rule: if shares close >15% down from pre-guidance levels after the rights are priced and management secures >12 months runway, consider building a 2–4% NAV long position over 2–6 weeks, otherwise stay sidelined until demonstrable revenue/contract traction.